Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt.

OTCPK:RGED.F Stok Raporu

Piyasa değeri: US$5.6b

Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 5/6

Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt has been growing earnings at an average annual rate of 25.4%, while the Pharmaceuticals industry saw earnings declining at 0.3% annually. Revenues have been growing at an average rate of 12.4% per year. Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt's return on equity is 19.6%, and it has net margins of 28.2%.

Anahtar bilgiler

25.4%

Kazanç büyüme oranı

25.6%

EPS büyüme oranı

Pharmaceuticals Sektör Büyümesi6.0%
Gelir büyüme oranı12.4%
Özkaynak getirisi19.6%
Net Marj28.2%
Sonraki Kazanç Güncellemesi12 Nov 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Gelir ve Gider Dağılımı

Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.


Kazanç ve Gelir Geçmişi

OTCPK:RGED.F Gelir, gider ve kazançlar (HUF Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
30 Jun 24811,415229,129203,36384,358
31 Mar 24798,937187,874199,58483,924
31 Dec 23805,158158,850196,61978,344
30 Sep 23825,94895,563201,66778,574
30 Jun 23855,211123,426199,70477,387
31 Mar 23844,351157,720191,46975,290
31 Dec 22802,755169,076182,35075,109
30 Sep 22755,061242,521165,81668,730
30 Jun 22694,772198,297155,13566,489
31 Mar 22657,758149,792146,77362,419
31 Dec 21630,595139,626143,26161,005
30 Sep 21604,708114,689139,57559,304
30 Jun 21584,88799,067136,05956,079
31 Mar 21566,244102,570132,52554,418
31 Dec 20566,776104,683133,76653,977
30 Sep 20555,12468,482134,35855,110
30 Jun 20544,96468,130137,59653,745
31 Mar 20527,60854,123144,86652,273
31 Dec 19507,79447,135145,28148,860
30 Sep 19490,66849,451144,04346,258
30 Jun 19462,57636,071143,72043,363
31 Mar 19453,15142,857141,65040,903
31 Dec 18445,48435,348139,65440,545
30 Sep 18434,07811,939140,52341,576
30 Jun 18441,99718,899139,25340,768
31 Mar 18445,6262,997139,41241,027
31 Dec 17444,3568,885138,25639,903
30 Sep 17439,82268,291137,88237,763
30 Jun 17429,20766,829136,12136,317
31 Mar 17413,02174,992131,93235,489
31 Dec 16389,69066,200127,90335,153
30 Sep 16372,68952,016122,48632,401
30 Jun 16368,53944,525120,79233,588
31 Mar 16366,88950,419118,31833,813
31 Dec 15365,22053,863117,70734,822
30 Sep 15366,63140,482117,11040,072
30 Jun 15362,90339,300119,71442,380
31 Mar 15353,08030,652119,71342,996
31 Dec 14353,70924,950121,31543,666
30 Sep 14355,04331,723126,41143,069
30 Jun 14348,76837,367123,44642,308
31 Mar 14354,34633,058126,46741,371
31 Dec 13351,88642,766126,31740,800

Kaliteli Kazançlar: RGED.F has high quality earnings.

Büyüyen Kar Marjı: RGED.F's current net profit margins (28.2%) are higher than last year (14.4%).


Serbest Nakit Akışı ve Kazanç Analizi


Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: RGED.F's earnings have grown significantly by 25.4% per year over the past 5 years.

Büyüme Hızlandırma: RGED.F's earnings growth over the past year (85.6%) exceeds its 5-year average (25.4% per year).

Kazançlar vs. Sektör: RGED.F earnings growth over the past year (85.6%) exceeded the Pharmaceuticals industry 13%.


Özkaynak Getirisi

Yüksek ROE: RGED.F's Return on Equity (19.6%) is considered low.


Varlık Getirisi


Kullanılan Sermaye Getirisi


Geçmişte güçlü performans gösteren şirketleri keşfedin